Stockreport

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World [Yahoo! Finance]

Arcellx, Inc.  (ACLX) 
PDF Multiple Myeloma to be Presented by Partner Arcellx; Follows Progress with First Patient Dosed in Phase 3 iMMagine-3 Study – – Survival Rate for Yescarta ® Supported b [Read more]